This study focuses on the application of novel low-dose IL2 therapy in these two autoimmune diseases i.e. SLE and RA, as well as the comparability of these new interventions’ efficacy and safety among patients of SLE and RA. The gene discussed is IL2; the disease is rheumatoid arthritis.